At its Meeting on 30 May 2022, the Transparency Council adopted Position No. 52/2022 on the evaluation of Lynparza (olaparibum) under the drug programme:: “Treatment of patients with metastatic or ineligible for radical treatment pancreatic adenocarcinoma with BRCA 1/2 gene mutations (ICD-10 C 25.0, C 25.1, C 25.2, C 25.3, C 25.5, C 25.6, C 25.7, C 25.8, C 25.9)”.